Paxmedica ceo interviewed by the brain foundation

Webcast link available at paxmedica.com tarrytown, ny, june 20, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced that its ceo, howard weisman, participated in a webcast on saturday, june 17th, hosted by the brain foundation.  the core content of the webcast was an interview with mr.
PXMD Ratings Summary
PXMD Quant Ranking